TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Administration of Trastuzumab (Herceptin) by a Single-use Injection Device Versus a Handheld Syringe

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male patients, 18 to 45 years of age, inclusive~* No history of hypersensitivity or allergic reactions following drug administration~* No history of clinically significant or clinically relevant cardiac condition~* No history of previous anticancer treatment~* Body mass index (BMI) between 18-32 kg/m2, inclusive~Exclusion Criteria:~* Positive test result for drugs of abuse~* Positive test result for hepatitis B, hepatitis C, or HIV 1 or 2~* Systolic blood pressure greater than 140 mmHG or less than 90 mmHG, or diastolic blood pressure greater than 90 mmHG or less than 50 mmHG~* Clinically significant abnormal laboratory values

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tumor Gene Expression in Women With Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has intraabdominal disease either proven or strongly suspected to be ovarian or primary peritoneal cancer, and will be undergoing surgical debulking.~* Subject is not allergic to dexamethasone, and there is no obvious medical contraindication to dexamethasone.~* Subjects with diabetes requiring drug therapy are excluded.~* Subject is not currently receiving glucocorticoid therapy~* Nasal steroids (e.g. Flonase) are permitted~* Subject understands that this protocol does not have therapeutic intent~* Preoperative serum albumin at least 3.0 mg/dL~* Negative serum or urine pregnancy test in women of childbearing potential~* Signed informed consent~Exclusion Criteria:~* Males do not get ovarian cancer and therefore will not be included in this trial.~* Patients of all ethnic backgrounds are eligible and will be encouraged to enroll. However we do not expect differences based on ethnicity, and this small study will not therefore be powered to make conclusions about ethnic differences in induction of GR-regulated genes with dexamethasone.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: ACTIVE_COMPARATOR): 20 mg of dexamethasone
- Placebo [Saline] (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epiduo Pediatric Acne Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of acne vulgaris with facial involvement~* Score of 3 (moderate) on the Investigator's Global Assessment (IGA) scale~* A minimum of 20 but not more than 100 total lesions (Noninflammatory and/or Inflammatory) on the face (including the nose) at Baseline~Exclusion Criteria:~* Acne nodule or acne cyst~* Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring systemic treatment~* Underlying diseases and/or dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments~* Use of prohibited medications prior to the study and/or are unwilling to refrain from such use during the study

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- adapalene/benzoyl peroxide (Type: ACTIVE_COMPARATOR): Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks
- Topical Gel Vehicle (Type: PLACEBO_COMPARATOR): Topical Gel Vehicle applied topically once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult aged 18-65~* Able to give informed consent~Exclusion Criteria:~* Known chronic illness~* Hb \<7 at baseline~* Liver function or Creatinine \* 1.5 Upper Limit of Normal~* Urinary tract infection at baseline~* Pregnancy (female participants only)~* Routine medications which interact with study drugs~* Lactose/Gluten intolerance~* Permanent disability impeding study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Azithromycin for Yaws (Type: ACTIVE_COMPARATOR): Patients will receive standard treatment for yaws alone
- IDA for Lymphatic Filariasis (Type: ACTIVE_COMPARATOR): Patients will receive standard IDA (Ivermectin \& Diethylcarbamazine \& Albendazole) treatment for Lymphatic Filariasis alone
- Combination Therapy of Azithromycin for Yaws and IDA for LF (Type: EXPERIMENTAL): Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of low tumor burden, CD20-positive follicular lymphoma~* Ann Arbor Stage II, III, or IV~Exclusion Criteria:~* Not a candidate for treatment with rituximab as a single-agent~* Evidence of transformation to a high grade or diffuse large B-cell lymphoma~* Any previous systemic therapy for B-cell NHL, including chemotherapy, immunotherapy, or steroids~* Any prior treatment with rituximab~* Active, uncontrolled infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-05280586 (Type: EXPERIMENTAL): None
- MabThera® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple sclerosis~* Receiving Ampyra® consistently for at least 2 weeks prior to the screening visit~* No history of seizures except simple febrile seizures~Exclusion Criteria:~* Sexually active woman of childbearing potential who is not surgically sterile, \<two years post-menopause or is not using effective birth control methods~* Subject who is pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- dalfampridine-ER 10mg (Type: None): Subjects with MS taking dalfampridine-ER 10mg and considered to be responders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Hyaluronic Acid on Perimplantitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Implants with at least one year of functional load.~* Implants diagnosed with peri-implantitis according to the criteria of the Association of Dental Implantology.~Exclusion Criteria:~* Previous peri-implantitis treatment.~* Pregnancy or breast-feeding.~* Neoplastic disease.~* Antibiotic treatment during the previous month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Test Group (Type: EXPERIMENTAL): Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
- Control 1 Group (Type: SHAM_COMPARATOR): Hydroxypropyl guar based gel, without any biological effect.
- Control 2 Group (Type: NO_INTERVENTION): No gel application, only standard perimplantitis treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed VIN (only usual type, formerly VIN 2-3)~* Visible, measurable lesion(s)~* Contraception (for premenopausal women)~Exclusion Criteria:~* Evidence of invasion~* History of cancer or severe inflammatory dermatosis of the vulva~* Pregnancy, lactation~* Immunodeficiency~* Any treatment for VIN within the previous three months~* Known hypersensitivity to imiquimod

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Primary Imiquimod (Type: EXPERIMENTAL): Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
- Primary surgery (Type: ACTIVE_COMPARATOR): The type of surgery (excision or ablation) will be based on clinical findings and surgeon's judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Portion A: Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy or B cell lymphoma, for which no curative therapy is available. Portion A expansion includes patients who have documented disease progression on a checkpoint inhibitor (anti CTLA 4, anti PD1/PD L1 antibodies) per RECIST criteria. Tumor types include metastatic melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NCSLC) and squamous cell carcinoma of the head and neck (SCCHN). Patients in the dose expansion stage are required to provide archival or baseline (obtained during the screening period) tumor biopsies.~* Portion B: Histological confirmed relapsed or refractory CD20 positive NHL for which no curative therapy is available. Patients enrolled in the expansion cohort must have archival tissue available, sampled within 6 months of study entry. The Expansion cohort includes patients with FL or DLBCL with relapsed or refractory disease.~* Measurable disease with at least one extranodal tumor mass \>1.0 cm in the greatest transverse diameter (GTD) or in the case of malignant lymph nodes \>1.5 cm in the GTD.~* ECOG performance status of ≤ 1.~* Adequate bone marrow function, for Portion A: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥100 x 109/L, hemoglobin \>9.0 g/dL. For Portion B: ANC ≥ 1.0 x 109/L, platelet count ≥ 75 x 109/L, and hemoglobin ≥ 8.0 g/dL. In both cases, patients must be transfusion independent at least 14 days prior to screening.~* Serum creatinine ≤ 2 x ULN or estimated creatinine clearance ≥ 50 ml/min.~* Total serum bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome and AST and ALT ≤ 2.5 x ULN.~Exclusion Criteria~* Patients with known symptomatic brain metastases requiring steroids.~* Prior allogeneic hematopoietic stem cell transplant.~* Immunosuppressive regimens involving systemic corticosteroids within 14 days before the first dose of study treatment.~* Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation therapy within 14 days of the first dose of study drug.~* Autoimmune disorders and other diseases that compromise or impair the immune system.~* Unstable or serious concurrent medical conditions in the previous 6 months.~* Prior therapy with any anti CD137 monoclonal antibody.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Portion A (Type: EXPERIMENTAL): PF-05082566 single agent in patients with advanced cancer
- Portion B (Type: EXPERIMENTAL): PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Morphine IV vs Paracetamol IV in Neonates and Infants After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Neonates/infants who are 0-36 months old~* Cardiac surgery with the use of CPB.~Exclusion Criteria:~* No informed consent~* Known allergy to or intolerance of paracetamol or morphine~* Administration of opioids in the 24 h prior to surgery~* Hepatic dysfunction defined as three times the reference value of alanine aminotransferase/aspartate aminotransferase (ALAT/ASAT)~* Renal insufficiency at least RIFLE category Risk prior to surgery.

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- morphine (Type: OTHER): Standard care, continuous morphine IV.
- paracetamol (Type: ACTIVE_COMPARATOR): intervention group, intermittent paracetamol IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ginger Capsules for the Acute Treatment of Migraine Attacks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria:~  * Migraine diagnosis for at least one year;~ * Migraine attack with moderate or severe pain intensity;~ * One to six migraine attacks per month.~* Exclusion Criteria:~  * Patients with headaches not characterized as migraine;~ * Pregnant or lactating women;~ * Fertile and sexually active women who do not use contraception;~ * Abuse of painkillers, alcohol or drugs;~ * People with hypersensitivity to ginger;~ * People with other neurological diseases;~ * People in use of anticoagulant drugs;~ * People who have started the disease after 50 years old.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Extract of ginger (Type: EXPERIMENTAL): People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols) and intravenous ketoprofen (100mg).
- Cellulose (Type: PLACEBO_COMPARATOR): People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female inpatients, 18-65 years of age, meeting DSM-IV-TR criteria for schizophrenia and having a Total Positive and Negative Syndrome Scale (PANSS) Score \>=80 and \<=120. A score \>=4 on item P1 (delusions) or P3 (hallucinatory behavior) and a score of \>=4 on item P2 (conceptual disorganization) or P6 (suspiciousness/persecution) of the PNASS~Exclusion Criteria:~* Patients with documented disease of the central nervous system that can interfere with the trial assessments, including but not limited to stroke, tumor, Parkinson's, organic brain disease, seizure disorder (except for febrile convulsions during infancy), chronic infection, or neurosyphilis; or patients who have suffered a traumatic brain injury resulting in significant impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* 18 years~* Histologically confirmed non-curable NSCLC with an estimated total tumor burden volume of less than or equal to 125 cc, confirmed to be stage II, III, or IV.~* Must have completed or refused conventional therapy~* Performance status (ECOG) less than 2.~* Absolute granulocyte count greater than or equal to 1,500/mm3~* Platelet count greater than or equal to 100,000/mm3~* Total Bilirubin less than or equal to 2 mg/dL~* AST and ALT less than or equal to 2x Upper Limit of Normal~* Creatinine less than or equal to 1.5 mg/Dl~Exclusion Criteria:~* Concurrent systemic steroids greater than 2 mg prednisone/day~* Prior splenectomy~* Any surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy or immunotherapy less than 4 weeks of study entry~* Brain metastases or meningeal lymphomatosis unless treated and stable for ≥ 2 months~* Known HIV positive~* Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives.~* Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for greater than or equal to 2 years~* Treatment with an investigational drug within 30 days prior to study entry~* History of psychiatric disorder that would impede adherence to protocol~* Pregnant or nursing women or refusal to practice contraception if of reproductive potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lucanix (Type: EXPERIMENTAL): Patients will receive injections of Lucanix for each dose cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete